IDH1/2 Inhibitor

LY3410738

Type of Alteration(s)
Point Mutations
Alteration(s) of Interest**
IDH1 R132C/L/G/S/H
IDH2 R172K/M/G/W
Methodology
Key Considerations
NGS (Tissue)
  • Suitable for broad-based genomic profiling that includes targets in addition to IDH1/IDH2
  • Able to detect all possible IDH1/IDH2 mutations
  • Detection may require higher tumor content than PCR-based assays
PCR-based
  • Will detect selected mutations but may miss novel IDH1/IDH2 alterations
NGS (cfDNA)
  • Useful when tissue biopsy sample is limited/unavailable
  • Higher false negative rate than tissue-based NGS testing
Sanger Sequencing
  • Able to detect all possible IDH1/IDH2 mutations within an exon
  • Detection may require higher tumor content than PCR-based assays
*
IDH1 mutations more common than IDH2 mutations in CCA
References
1. Boscoe AN et al. J Gastrointest Oncol. 2019;10(4) 2. Yang H et al. Clin Cancer Res. 2012;18(20)

Check Clinical Trials information to see if patient qualifies

Need additional information or have a question:

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.